64th ASH Annual Meeting and Exposition: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Prognostic Factors in Newly Diagnosed Multiple Myeloma (NDMM)

Symposia: Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological Oral and Poster Abstracts
Oral

Research, Biological therapies, Translational Research, Clinical Practice (Health Services and Quality), Clinical Research, Plasma Cell Disorders, bioinformatics, Combination therapy, health outcomes research, Diseases, patient-reported outcomes, Therapies, real-world evidence, Lymphoid Malignancies, computational biology, Biological Processes, Monoclonal Antibody Therapy, survivorship, Technology and Procedures, Study Population, multi-systemic interactions, Human, Minimal Residual Disease , imaging, omics technologies

New Orleans Theater C (Ernest N. Morial Convention Center)

Moderators:

Joshua Richter, MD, Icahn School of Medicine at Mount Sinai and Adriana Rossi, MD, MSc, Weill Cornell Medicine

Disclosures:

Richter: BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Regeneron: Other: travel; Adaptive Biotechnologies: Speakers Bureau; Karyopharm: Consultancy, Honoraria.

9:30 AM

469

Circulating Clonal Plasma Cells at Diagnosis and Peripheral Blood Measurable Residual Disease Assessment Provide Powerful Prognostication Biomarkers in Newly-Diagnosed Multiple Myeloma Patients Treated without Autologous Transplant

Prashant Ramesh Tembhare, MD^1,2^*, Harshini Sriram, M.Sc.^3,4^*, Twinkle Khanka, M.Sc.³^*, Sanghamitra Gawai, BSc³^*, Sitaram Ghogale, BSc³^*, Nilesh Deshpande, BSc³^*, Bhausaheb Bagal, MD, DM^4,5,6^*, Gaurav Chatterjee, MD⁷^*, Syed Khizer Hasan, PhD⁸^*, Sweta Rajpal, MD, DM^3,4^*, Nikhil Patkar, MD^4,9^*, Hasmukh Jain, MD, DM^10,11^*, Dhanlaxmi Lalit Shetty, PhD¹²^*, Kinjalka Ghosh, MD¹³^*, Nitin Inamdar, PhD¹⁴^*, Sachin Punatar, MD, DM^4,15^*, Anant Gokarn, MD, DM^4,16^*, Manju Sengar, MD, DM^17,18, Navin Khattry, MD, DM¹⁹^*, Papagudi Ganesan Subramanian, MD^4,7^* and Sumeet Gujral, MD^4,20^*

¹Homi Bhabha National Institute., Mumbai., India
²Hematopathology Laboratory, ACTREC, Tata Memorial Center, Navi Mumbai, India, India
³Hematopathology Laboratory, ACTREC, Tata Memorial Centre, Navi Mumbai, India
⁴Homi Bhabha National Institute, Mumbai, India
⁵Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India
⁶Adult Hematolymphoid Disease Management Group, Department of Medical Oncology, Tata Memorial Centre, Mumbai, India
⁷Hematopathology Laboratory, ACTREC, Tata Memorial Centre, Navi Mumbai, Maharashtra, India
⁸ACTREC, Tata Memorial Centre, Navi Mumbai, India
⁹Haematopathology Laboratory, Tata Memorial Hospital, Tata Memorial Centre, Affiliated to Homi Bhabha National Institute, Navi Mumbai, India
¹⁰Adult Hematolymphoid Disease Management Group, Tata Memorial Centre, Mumbai, India
¹¹Department of Medical Oncology, Tata Memorial Center, Mumbai, India
¹²Adult Hematolymphoid Disease Management Group, Department of Medical Oncology, ACTREC, Tata Memorial Centre, Navi Mumbai, Maharashtra, IND
¹³Department of Biochemistry, Tata Memorial Centre, Affiliated to Homi Bhabha National Institute, Mumbai, India
¹⁴Department of Biochemistry, Tata Memorial Centre, India, Mumbai, India
¹⁵Department of Medical Oncology, Tata Memorial Centre, Mumbai, India
¹⁶BMT Unit, Department of Medical Oncology, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Mumbai, India
¹⁷Homibhaba National Institute, Mumbai, India, MUMBAI, India
¹⁸Hematolymphoid Disease Management Group, Department of Medical Oncology, Tata Memorial Centre, Mumbai, India
¹⁹Department of Bone Marrow Transplant, ACTREC, Tata Memorial Centre, Navi Mumbai, India
²⁰Hematopathology Laboratory, Tata Memorial Centre, Mumbai, India

9:45 AM

470

Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy

Francesco Maura, MD¹, Eileen Boyle²^*, David Coffey, MD¹, Kylee H Maclachlan, MBBCh, PhD³, Benjamin Diamond¹^*, Patrick Blaney, MS²^*, Dylan Gagler, MS⁴^*, Bachisio Ziccheddu, PhD⁵^*, Hussein Ghamlouch, PhD²^*, Yubao Wang, PhD²^*, James E. Hoffman, MD¹^*, Dickran Kazandjian, MD¹, Hani Hassoun, MD³, Emily Guzman²^*, Sham Mailankody, MBBS ⁶, Urvi A Shah, MD³, Carlyn Tan, MD³, Malin Hultcrantz, MD, PhD³, Michael Scordo, MD⁷, Gunjan L. Shah, MD⁸^*, Heather Landau, MD⁷, David J. Chung, MD, PhD³, Sergio A. Giralt, MD, FACP, FASTCT⁶^*, Yanming Zhang, MD³, Ahmet Dogan, MD, PhD³, Alexander M Lesokhin, MD³, Dennis Verducci¹^*, Faith E. Davies, MD²^*, Saad Usmani, MD⁶, Neha Korde, MD³, Gareth J. Morgan, MD² and Ola Landgren, MD⁵

¹Myeloma Division, University of Miami, Sylvester Comprehensive Cancer Center, Miami
²NYU Langone, Perlmutter Cancer Center, New York
³Memorial Sloan Kettering Cancer Center, New York
⁴Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Health, New York, NY
⁵Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
⁶Memorial Sloan Kettering Cancer Center, New York, NY
⁷Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁸Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

10:00 AM

471

Failure to Achieve Sustained Imaging MRD Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Is Associated with Adverse Prognosis in Newly Diagnosed Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation Followed By Maintenance Therapy

Angelo Belotti, MD¹^*, Rossella Ribolla, MD¹^*, Claudia Crippa, MD¹^*, Marco Chiarini, MSc²^*, Viviana Giustini, MSc²^*, Samantha Ferrari, MD¹^*, Annalisa Peli, MD¹^*, Chiara Cattaneo, MD³^*, Aldo Roccaro, MD, PhD⁴, Barbara Frittoli, MD⁵^*, Marta Salis, MD⁵^*, Luigi Grazioli, MD⁶^*, Giuseppe Rossi, MD⁷ and Alessandra Tucci, MD¹^*

¹Hematology, ASST Spedali Civili di Brescia, Brescia, Italy
²Flow Cytometry Unit, Clinical Chemistry Laboratory, ASST Spedali Civili di Brescia, Brescia, Italy
³Hematology, ASST Spedali Civili di Brescia, Brescia, BS, Italy
⁴Clinical Research Development and Phase I Unit, ASST Spedali Civili di Brescia, Brescia, Italy
⁵Radiology, ASST Spedali Civili di Brescia, Brescia, Italy
⁶Radiology, ASST- Spedali Civili di Brescia, brescia, Italy
⁷Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy

10:15 AM

472

Aurore Perrot, MD, PhD¹^*, Thierry Facon²^*, Torben Plesner³, Saad Usmani, MD⁴, Shaji K Kumar, MD⁵, Nizar Jacques Bahlis, MD⁶, Cyrille Hulin⁷^*, Robert Z. Orlowski, MD, PhD⁸, Hareth Nahi⁹^*, Peter Mollee¹⁰, Karthik Ramasamy¹¹, Murielle Roussel¹²^*, Arnaud Jaccard¹²^*, Michel Delforge¹³, Lionel Karlin¹⁴^*, Bertrand Arnulf¹⁵^*, Ajai Chari¹⁶^*, Huiling Pei, PhD¹⁷^*, Niodita Gupta¹⁸^*, Shuchita Kaila¹⁸^*, Kathryn Matt¹⁸^*, Katharine S. Gries, PhD, PharmD¹⁹^*, Robin Carson²⁰, Fredrik Borgsten¹⁹^* and Katja C. Weisel, MD²¹

¹Centre Hospitalier Universitaire de Toulouse, Service d'Hématologie, Toulouse, France
²University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France
³Vejle Hospital and University of Southern Denmark, Vejle, Denmark
⁴Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁵Mayo Clinic, Rochester, MN
⁶Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada
⁷University Hospital, Hôpital Haut Lévêque, Pessac, France
⁸The University of Texas MD Anderson Cancer Center, Houston, TX
⁹Karolinska Institute, Karolinska University Hospital at Huddinge, Stockholm, Sweden
¹⁰Princess Alexandra Hospital, Woolloongabba, Australia
¹¹Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
¹²Service d'hématologie clinique et de thérapie cellulaire, CHU de Limoges, Limoges, France
¹³Universitaire Ziekenhuizen Leuven, Leuven, Belgium
¹⁴Hematology Department, Lyon University Hospital, Pierre-Benite, France
¹⁵Department of Immuno-hematology, Hôpital Saint Louis, APHP, Paris, France
¹⁶Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY
¹⁷Janssen Research & Development, LLC, Titusville, NJ
¹⁸Janssen Scientific Affairs, LLC, Horsham, PA
¹⁹Janssen Research & Development, Raritan, NJ
²⁰Janssen Research & Development, Spring House, PA
²¹University Medical Center Hamburg-Eppendorf, Hamburg, Germany

10:30 AM

473

Rebecca Silbermann, MD, MMS¹, Jacob Laubach, MD², Jonathan L. Kaufman, MD³, Douglas W. Sborov, MD⁴, Brandi Reeves, MD⁵, Cesar Rodriguez, MD⁶^*, Ajai Chari, MD⁷, Luciano J. Megala Costa, MD, PhD⁸, Larry D. Anderson Jr., MD, PhD⁹, Nitya Nathwani, MD¹⁰, Nina Shah, MD¹¹, Naresh Bumma, MD¹², Sarah A. Holstein, MD, PhD¹³, Caitlin Costello, MD¹⁴, Andrzej Jakubowiak, MD, PhD¹⁵, Robert Z. Orlowski, MD, PhD¹⁶, Kenneth H. Shain, MD, PhD¹⁷, Andrew J. Cowan, MD¹⁸^*, Katharine S. Gries, PhD, PharmD¹⁹^*, Huiling Pei, PhD²⁰^*, Annelore Cortoos, MD²¹^*, Sharmila Patel, PhD²¹^*, Thomas S. Lin, MD, PhD²¹, Paul G. Richardson, MD²², Saad Usmani, MD²³ and Peter M. Voorhees, MD²⁴^*

¹Knight Cancer Institute, Oregon Health & Science University, Portland, OR
²Dana-Farber Cancer Institute, Boston, MA
³Winship Cancer Institute of Emory University Hospital, Atlanta, GA
⁴Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
⁵University of North Carolina – Chapel Hill, Chapel Hill, NC
⁶Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
⁷Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY
⁸University of Alabama at Birmingham Hospital, Vestavia, AL
⁹Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX
¹⁰Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte, CA
¹¹Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA
¹²Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH
¹³Division of Oncology & Hematology, University of Nebraska Medical Center, Omaha, NE
¹⁴Moores Cancer Center, University of California San Diego, La Jolla, CA
¹⁵University of Chicago Medical Center, Chicago, IL
¹⁶Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
¹⁷Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
¹⁸Division of Medical Oncology, University of Washington, Seattle, WA
¹⁹Janssen Research & Development, Raritan, NJ
²⁰Janssen Research & Development, LLC, Titusville, NJ
²¹Janssen Scientific Affairs, LLC, Horsham, PA
²²Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
²³Memorial Sloan Kettering Cancer Center, New York, NY
²⁴Levine Cancer Institute, Atrium Health Wake Forest Baptist, Charlotte, NC

10:45 AM

474

Prognostic Significance of Circulating Plasma Cells Detected By Next Generation Flow Cytometry in Light (AL) Chain Amyloidosis

Efstathios Kastritis, MD¹^*, Ioannis V Kostopoulos, PhD²^*, Foteini Theodorakakou, MD³^*, Pantelis Roussakis, MSc²^*, Chrysanthi Panteli²^*, Nikolaos Orologas-Stavrou²^*, Vasiliki Spiliopoulou, MD¹^*, Magdalini Migkou, MD³^*, Asimina Papanikolaou, MD⁴^*, Harikleia Gakiopoulou⁵^*, Despina Fotiou, MD¹^*, Evangelos Terpos, MD, PhD³, Ourania E. Tsitsilonis, MD, PhD²^* and Meletios A. Dimopoulos, MD¹

¹Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
²Department of Biology, National and Kapodistrian University of Athens, School of Science, Athens, Greece
³Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
⁴Department of Hemopathology, "Evangelismos" General Hospital, Athens, Greece
⁵1st Department of Pathology, National & Kapodistrian University of Athens, School of Medicine,, Athens, Greece

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

652A.O2.6 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Prognostic Factors in Newly Diagnosed Multiple Myeloma (NDMM)